Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prelude Therapeutics (PRLD) Change in Acquisitions & Divestments (2024 - 2025)

Historic Change in Acquisitions & Divestments for Prelude Therapeutics (PRLD) over the last 2 years, with Q3 2025 value amounting to $40.1 million.

  • Prelude Therapeutics' Change in Acquisitions & Divestments fell 630.75% to $40.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $177.5 million, marking a year-over-year change of. This contributed to the annual value of $143.6 million for FY2024, which is 2459.37% down from last year.
  • Latest data reveals that Prelude Therapeutics reported Change in Acquisitions & Divestments of $40.1 million as of Q3 2025, which was down 630.75% from $36.2 million recorded in Q2 2025.
  • In the past 5 years, Prelude Therapeutics' Change in Acquisitions & Divestments registered a high of $71.7 million during Q1 2025, and its lowest value of $29.5 million during Q4 2024.